- Price
- $11.92
- Day
- +0.08%
- Mkt Cap
- $1.00B
- 52W Range
- $1.50 – $13.86
- Volume
- 6.00M
- Beta
- 0.87
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Replimune Group Inc. (NASDAQ:REPL) stock more than doubled on Friday after the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted in favor of the company's IGNYTE study data.
Read full article
Shares of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's panel of outside advisers voted to back trial results for its drug for a type of skin cancer.
Read full article
LOS ANGELES, July 31, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company's possible violations of the federal securities laws.
Read full article
Independent experts voted 10-3 despite regulators' concern about the design of the company's pivotal cancer trial.
Read full article
A panel of outside advisers to the US Food and Drug Administration voted to back results from a trial studying Replimune's drug for a type of skin cancer in a meeting on Thursday.
Read full article
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read full article
WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's meeting of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), which discussed the Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
Read full article
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
Read full article
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Read full article
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REPLIMUNE GROUP INC. (REPL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by.
Read full article
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON REPLIMUNE GROUP INC. (REPL) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened.
Read full article
SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. (NASDAQ: REPL) or certain of its executive officers violated state or federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Read full article